Views on Prescription Drug Pricing and Medicare-for-all Proposals

Views on Prescription Drug Pricing and Medicare-for-all Proposals

Kaiser Health Tracking Poll – March 2018

Computer-assisted telephone interviews conducted by landline and cell phone were carried out in English and Spanish by SSRS

The March Kaiser Health Tracking Poll finds that more than a year into President Trump’s presidency, half of the public (52 percent) say passing legislation to bring down the price of prescription drugs should be a “top priority” for President Trump and Congress. Yet, less than half of the public (39 percent) say they are confident that President Trump and his administration will be able to deliver on the promise that Americans will pay less for prescription drugs than they pay now.

Pharmaceutical companies rank among the top organizations that the public – including majorities of Democrats, independents, and Republicans – say has “too much influence” in Washington. Seven in ten (72 percent) say pharmaceutical companies have “too much influence,” which is similar to other entities like large businesses and Wall Street, but much higher than the shares of the public who say the National Rifle Association (NRA), hospital groups, or doctors groups have “too much influence” (52 percent, 36 percent, 30 percent, respectively). There is stronger agreement among partisans on the influence of pharmaceutical companies with majorities of both Democrats (65 percent) and Republicans (74 percent) saying pharmaceutical companies have “too much influence” in Washington.